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doi:10.1016/j.ejvs.2011.08.016Abstract Objectives: Few data are available on thrombophilic risk factors and clinical
outcome in patients undergoing percutaneous transluminal angioplasty (PTA) for peripheral
arterial disease (PAD). We investigated the role of homocysteine, fibrinogen, Factor VIII (FVIII),
lupus anticoagulant (LAC) and FII G20210A, and FV R506Q (FV Leiden) mutations as prognostic
factors in 230 patients who underwent PTA for PAD (Fontaine’s stages: IIb through IV; aged
69  1 years).
Design and methods: A prospective study. Major adverse cardiovascular events (MACE) were
the composite ‘end’ point.
Results: During the follow-up (24.3  1.5 months), 96 (41.7%) patients reached the ‘end’ point.
According to Cox regression analysis, diabetes and critical limb ischaemia were predictors of
MACE, whereas each single thrombophilic alteration was not. Thrombophilic alterations were
more frequent in patients that reached the ‘end’ point, and the patients with two alterations
(hazard ratio (HR) 2.55 confidence interval (CI): 1.20e5.46, pZ 0.015) and those with three or
more alterations (HR 2.91 CI: 1.31e6.45, p Z 0.009) had an increased risk for MACE versus
those without alterations. Thrombophilic alterations were not associated with limb loss during
the follow-up.
Conclusion: The presence of multiple thrombophilic alterations in patients who underwent
PTA for PAD is associated with increased risk of arterial thrombotic events.
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818 M. Sartori et al.Lower limb peripheral arterial disease (PAD) is a common,
important manifestation of systemic atherosclerosis.
Intermittent claudication is usually the first symptom and
remains stable in 75% of patients while progression leading
to clinical deterioration (severe claudication or skin lesions)
occurs in the remainder.1 Atherosclerosis of the lower
extremities leading to lifestyle-restricting claudication or
critical limb ischaemia (CLI) is commonly treated by lower
extremity revascularisation.2 It has been shown that
patients with PAD, undergoing elective major vascular
surgery, presented an elevated mortality rate during
follow-up, reaching 11% after 1 year.3 Various biomarkers
have been evaluated to identify patients with unstable
plaques and subsequently predict future clinical events.4
Homocysteine, Factor VIII (FVIII), lupus anticoagulant
(LAC) and genetic polymorphisms of haemostatic factors
such as G20210A prothrombin (FII) and R506Q FV (FV Lei-
den) are well-known risk factors for deep vein thrombosis.5
They may be involved in arterial thrombosis and may
interact with traditional cardiovascular risk factors,
prompting vascular disease and complications.6 Recently,
we showed that altered levels of some important throm-
bophilic risk factors are independently associated with PAD
severity,7 and such abnormalities could predict the
outcome of PAD patients undergoing endovascular proce-
dures for lower limb atherosclerotic stenoses. The aim of
the present study was to assess the impact of thrombophilic
abnormalities on the risk of cardiovascular events in PAD
patients undergoing percutaneous transluminal angioplasty
(PTA).
Methods
Study design
From 1 January 2003 to 1 June 2010, 230 consecutive
patients referred to our institution for PTA with or without
stenting by retrograde transfemoral access were evaluated
into this single-centre, prospective study. Subjects were
diagnosed with PAD if they had clinical symptoms of the
disease (intermittent claudication, rest pain or gangrene),
ankle-brachial index (ABI) <0.90 and significant stenoses of
leg arteries confirmed by duplex ultrasound examination.
Fontaine stages were assigned as previously described.7
Stages III and IV were grouped as CLI.8
Inclusion criteria were symptomatic PAD patients at
Fontaine stages IIbeIIIeIV that underwent femoro-popliteal
or iliac endovascular procedure. Exclusion criteria were
PAD caused by non-atherosclerotic causes (cardioembolic
disease, thromboangiitis obliterans, vasculitis or congen-
ital), previous deep vein thrombosis, the presence of
neoplasia, and severe dementia.
The design of the study was prospective: the study
started after patient discharge from our Unit. Each patient
was seen in the outpatient clinic of our Unit, after 1 month,
6 months, 1 year and every year thereafter. For the present
analysis, follow-up ended at 30 June 2010. At each visit,
clinical examination, ABI measurement and duplex sonog-
raphy were performed. During each visit, the physician in
charge checked whether patients were under best medical
treatment: the patients received a standard therapy thatincluded a statin and a platelet aggregation inhibitor
(aspirin or clopidogrel or ticlopidine) during the entire
follow-up period. For 1 month after PTA, clopidogrel was
added to all patients not already receiving thienopyridine.
When the femoro-popliteal endovascular procedure was
performed, enoxaparin 1 mg kg1 daily was added for 1
week. Patients were strongly recommended to follow
adequate diabetes control and to stop smoking completely.
In cases of hypertension, anti-hypertensive agents were
started.
The ‘end’ point of the present study was defined as
a composite ‘end’ point (major adverse cardiovascular
event, MACE) of all-cause death, myocardial infarction,
hospitalisation for rest unstable angina, stroke, percuta-
neous coronary intervention, coronary bypass surgery and
lower extremity and carotid surgery. When patients
reached the ‘end’ point, they exited the study.
Information about hospitalisation and MACE was gath-
ered by reviewing hospital discharge reports. Cause of
death was ascertained by examining death certificates and/
or by reviewing medical records. It was classified as either
cardiovascular or non-cardiovascular. Cardiovascular death
included death following myocardial infarction, serious
cardiac arrhythmias, congestive heart failure or stroke.
Sudden unexpected death was classified as cardiovascular.
Limb salvage calculations included all major amputa-
tions (below and above knee) but did not include minor
amputations (digit and transmetatarsal).
The study was performed according to the recommen-
dations of the Declaration of Helsinki. The study protocol
was approved by the local ethics committee. Written
informed consent was obtained for all patients.Patient data and definition
Demographic data and baseline clinical characteristics
were systematically recorded including patients’ age, sex,
smoking status, body mass index, blood pressure, co-
morbidities and medication. Hypertension was defined as
blood pressure above 140/90 mmHg examined repeatedly
or documented in the patient’s history and was considered
to be present in patients receiving anti-hypertensive
therapy. Hyperlipidaemia was defined according to the
Third Report of the National Cholesterol Education
Program.9 Subjects were considered diabetic if they used
glucose-lowering medication or had fasting blood glucose
levels of 126 mg dl1 or higher. Obesity was defined as
a body mass index equal or higher than 30 kg m2.Vascular investigations
All patients underwent bilateral ultrasonography assess-
ment of lower limb arteries and ABI determination. Ultra-
sonography investigation was carried out with an EnVisor C
HD instrument (Philips Medical System S.p.A, Monza, Italy),
according to the standardised method.10 ABI at rest was
calculated in accordance with the American Heart Associ-
ation recommendations.11
Table 1 Characteristics of the study population.
Age (years) 68.9  0.7 (IQR 15)
Male/Female 134/96
Obesity (%) 2.1
Hypertension (%) 70.0
Hyperlipidaemia (%) 54.8
Diabetes (%) 26.5
Smoking (%) 40.4
ABI 0.54  0.02 (IQR 0.35)
CLI (%) 42.6
Fibrinogen (mg/dl) 396  6 (IQR 110)
Homocysteine (mmol/l) 17.2  0.9 (IQR 7.35)
FVIII (IU/ml) 2.38  0.07 (IQR 0.99)
LAC (%) 19.7
FV R506Q (%) 3.9
FII G20210A PT (%) 3.3
ABI, ankle-brachial index at enrolment; CLI, critical limb
ischaemia; IQR, interquartile range.
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One month after patient discharge from our unit, blood was
collected from the antecubital vein into 0.109 mol l1 tri-
sodium citrate after overnight fasting; thrombophilia
screening was performed as previously described.7 Clotting
fibrinogen levels were measured according to Clauss
(normal range: 150e350 mg dl1).7 FVIII levels were
determined using a chromogenic assay as described else-
where12 (normal values: <2.36 and <2.80 IU ml1 for
patients 50 and >50 years, respectively). Plasma levels of
total homocysteine (free and protein bound) were deter-
mined by fluorescence polarisation immunoassay (normal
values: <17 and <18 mmol l1 for males 45 and >45 years,
respectively and <12 and <14 mmol l1 for females 45 and
>45 years, respectively). Factor V R506Q Leiden and FII
G20210A mutations as well as LAC diagnosis tests were
performed using the methods previously described.7 In case
of positive determination, LAC assay was repeated in
a blood sample collected 1 month after the first positive
determination. All measurements were blinded to patient
identity.
Statistical analysis
Analysis was carried out using the Statistical Package for
Social Sciences (SPSS) software package (version 15; SPSS
Inc., Chicago, IL, USA). Relations between variables were
assessed using multiple linear regression analysis for
continuous variables and chi-square or Fisher’s exact test
for categorical variables. Cumulative ‘end’-point curves
were estimated with the KaplaneMeier procedure, and the
effect of the various variables on the ‘end’ point was
estimated from multivariate Cox’s proportional hazard
models.
With a sample size of 230 patients with thrombophilic
alterations in 30% of the group, the power of the study was
0.90 (a Z 0.05), assuming an increase of the frequency of
the ‘end’ point rate from 0.25 to 0.45 in the group with
thrombophilic alterations.
The significance level was set at a Z 0.05. Results are
given as means  SD, interquartile range and 95% confi-
dence interval.
Results
Among the 230 patients, 132 (57.4%) had severe claudica-
tion (Fontaine stage IIB), and 98 (42.6%) had CLI. A femoro-
popliteal endovascular procedure was performed in 136
patients, whereas an iliac procedure was performed in 94
patients; 113 procedures were PTA and 117 procedures
were PTA with stent placement (50.9%). Peri-procedural
complications occurred in 26 patients (6%), and included
eight groin haematomas, 13 distal embolisations, four
pseudo-aneuryms and one arteriovenous fistula.
Demographic data and atherosclerosis risk factors in the
whole population are reported in Table 1. Thrombophilic
risk factors are shown in Table 1. Six patients were
heterozygote for the FII G20210A mutation (claudication
n Z 1, CLI n Z 5), one patient at Fontaine’s stage IV was
homozygote for the FII mutation (age: 44 years) and eightpatients were heterozygote FV Leiden (claudication nZ 5,
CLI n Z 3). No homozygote for FV Leiden was observed.
During a mean study period of 24.3  1.5 months, MACE
were recorded in 96 (41.7%) patients including 35 (15.2%)
deaths (cardiovascular deaths n Z 20, including six sudden
unexpected deaths; non-cardiovascular deaths n Z 15), 23
non-fatal myocardial infarctions, nine hospitalisations for
rest unstable angina, 10 non-fatal strokes, 10 lower limb
amputation and nine abdominal aortic and carotid
surgeries. Patients with MACE had higher age (71  1 vs.
67  1 years, p Z 0.04), higher fibrinogen (414  10 vs.
381  8 mg dl1, p Z 0.008), higher FVIII (2.66  0.10 vs.
2.18  0.08 IU ml1, p Z 0.001) versus those who did not
reach the ‘end’ point, whereas homocysteine (18.1  1.4
vs. 16.4  1.1 mmol l1, pZ 0.334) and ABI (0.51  0.03 vs.
0.57  0.03, pZ 0.06) were similar in the two groups. The
frequency of MACE was higher in patients with CLI than in
those with claudication (54.1% vs. 32.6%, pZ 0.001), while
the frequency of MACE was similar in patients with the
femoro-popliteal endovascular procedure versus those with
the iliac procedure (42.6% vs. 40.4%, p Z 0.60). At
univariate analysis, diabetes (hazard ratio (HR) 3.16;
confidence interval (CI): 1.72e5.80; p Z 0.001), and CLI
(HR 2.44; CI: 1.42e4.18; p Z 0.001) were associated with
MACE, whereas hypertension (HR 0.90; CI: 0.51e1.60;
p Z 0.727), smoking (HR 0.60; CI: 0.35e1.10; p Z 0.085),
hyperlipidaemia (HR 0.83; CI: 0.49e1.40; p Z 0.486) and
LAC (HR 1.09; CI: 0.54e2.18; p Z 0.814) were not.
Among the patients with hereditary thrombophilia, two
heterozygote patients for the FV Leiden mutation and four
heterozygote patients for the FII mutation reached the
‘end’ point. The patient homozygote for the FII mutation
reached the ‘end’ point in the first month of follow-up.
According to a Cox multivariate model, the presence of
diabetes (HR 2.35; CI: 1.38-3.99; p Z 0.002) and CLI (HR
2.17; CI: 1.26e3.75; p Z 0.005) was associated with ‘end’
point, whereas age, fibrinogen, homocysteine, FVIII, LAC
and FV Leiden and FII mutations were not (Table 2).
Considering the variables: fibrinogen (normal values:
<350 mg dl1), homocysteine (normal values: <17 and
Table 2 Hazard risk of MACE according to multivariate
Cox analysis.
Variable HR CI 95% p
Age (year) 1.02 0.99e1.05 0.220
Diabetes 2.35 1.38e3.99 0.002
CLI 2.17 1.26e3.75 0.005
Fibrinogen (mg/dl) 1.01 0.99e1.01 0.299
Homocysteine (mmol/l) 1.00 0.99e1.02 0.758
FVIII (IU/ml) 1.18 0.82e1.71 0.380
Presence of LAC 1.32 0.70e2.50 0.389
Presence of FV Leiden 3.69 0.46e29.7 0.220
FII 20210A allele 1.07 0.31e3.68 0.921
CLI, critical limb ischaemia.
Figure 2 Estimate cumulative probability of reaching the
‘end’ point (MACE) in the patients with two or more throm-
bophilic alterations (unbroken line) and in those with one or
with no thrombophilic alterations (dotted line) considering as
dichotomous the following variables: fibrinogen, homo-
cysteine, FVIII, LAC, FII G20210A, and FV R506Q mutations
(normal values for age and sex reported in the method
section). * log-rank p Z 0.004.
820 M. Sartori et al.<18 mmol l1 for males 45 and >45 years, respectively
and <12 and <14 mmol l1 for females 45 and >45 years,
respectively), FVIII (normal values: <2.36 and
<2.80 IU ml1 for patients 50 and >50 years, respec-
tively), LAC, FII G20210A and FV Leiden mutations as
dichotomous, 40 patients presented no alteration, 97 one
alteration, 55 two alterations and 38 three or more alter-
ations. As reported in Fig. 1, the frequency of patients
reaching ‘end’ point increased from 22.5% in the group
without thrombophilic alterations to 50.0% in the group
with three or more alterations (p Z 0.033). HR for MACE
increased with the number of thrombophilic alterations:
1.39 (CI: 0.68e2.89; p Z 0.368) in patients with one
alteration, 2.55 (CI: 1.20e5.46; pZ 0.015) in patients with
two alterations and 2.91 (CI: 1.31e6.45; p Z 0.009) in
patients with three or more versus patients without alter-
ations. The KaplaneMeier estimated curves of probability
for reaching the ‘end’ point according to the presence/
absence of two or more thrombophilic alterations are re-
ported in Fig. 2. These show that patients with two or more
thrombophilic alterations have a higher risk of MACE than
those with one or no thrombophilic alterations. Because the
frequency of thrombophilic alterations increased in
patients with CLI versus those with claudication (1.6  0.1
vs. 1.3  0.1, p Z 0.006), a new Cox multivariate model100
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Figure 1 Percentage of patients reaching ‘end’ point (MACE)
according to the number of thrombophilic alterations, consid-
ering as dichotomous the following variables: fibrinogen,
homocysteine, FVIII, LAC, FII G20210A, and FV R506Q muta-
tions (normal values for age and sex reported in the method
section). *p < 0.05 vs. the group without thrombophilic
alterations.confirmed that the presence of at least two thrombophilic
alterations (HR 1.72; CI: 1.11e2.66; p Z 0.014) was asso-
ciated with ‘end’ point after adjustment for diabetes, CLI,
type of endovascular procedure and age (Table 3).
Limb salvage at 1, 3 and 5 years in the entire cohort was
95%  2%, 94%  2% and 92%  3%, respectively. Indepen-
dent predictors of limb loss on Cox proportional hazards
multivariate analysis included age (HR 1.01; CI: 1.00e1.01;
p Z 0.019) and CLI (HR 10.5; CI: 1.1e20.4; p Z 0.04),
whereas diabetes (HR 2.31; CI: 0.50e10.6; p Z 0.285),
femoro-popliteal versus iliac procedure (HR 2.66; CI:
0.98e7.21; p Z 0.055) and number of thrombophilic
alterations (HR 1.86; CI: 0.42e8.20; p Z 0.416) were not.
Discussion
The present study shows that in patients undergoing PTA for
PAD, no single thrombotic biomarker is associated with the
outcome, whereas the presence of multiple alterations
raises the likelihood of arterial thrombotic events. Throm-
bophilic alterations were not associated with the limb loss
during the follow-up. Patients with PAD undergoing endo-
vascular procedure present an elevated risk of cardiovas-
cular events during follow-up, and traditional
atherosclerotic risk factors are poor predictors of short-
term events. Thrombotic biomarkers could provide poten-
tially important prognostic information for clinicians that
may guide decisions regarding clinical work-up or therapy
intensity. Recently, we showed in a cross-sectional study
that the presence of two or more thrombophilic risk factors
raises the likelihood of PAD being more severe.7 It should be
noted that 54 patients in the present study participated in
both studies. In the present prospective study, the pres-
ence of two or more alterations increased the risk of
cardiovascular events in patients who underwent endovas-
cular procedures even after correction for PAD severity.
Moreover, the association between multiple thrombophilic
Table 3 Hazard Risk of MACE according to multivariate
Cox analysis, considering as dichotomous the following
variables: fibrinogen, homocysteine, FVIII, LAC, FII
G20210A, and FV R506Q mutations (normal values for age
and sex reported in the method section).
Variable HR CI 95% p
Age (year) 1.02 0.99e1.02 0.094
CLI 1.88 1.19e2.96 0.007
Diabetes 2.61 1.67e4.02 0.001
Femoro-popliteal PTAa 1.06 0.67e1.70 0.796
Thrombophilic alterations 2 1.72 1.11e2.66 0.014
CLI, critical limb ischaemia.
avs. iliac PTA.
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patients who participated in both studies. However, CLI was
an independent predictor of limb loss but not the number of
thrombophilic alterations.
Increased fibrinogen levels are associated with the
presence of PAD13 and with disease severity as measured by
ABI.14 In a large longitudinal study, fibrinogen was associ-
ated with progressive peripheral atherosclerosis.15
However, fibrinogen was not associated with development
of restenoses or reocclusions after endovascular treatment
of the femoro-popliteal artery.16,17 In our series, we were
unable to find a direct association between fibrinogen
plasma levels and cardiovascular events.
Several studies have already clearly established an
increased prevalence of hyperhomocysteinaemia in PAD
patients,18,19 but a few studies, and with contrasting
results, have investigated the relationship between homo-
cysteine and PAD outcome.20,21 A longitudinal study failed
to show any relationship between plasma levels of homo-
cysteine and PAD progression.22 Some studies failed to show
an association of homocysteine with development of
restenoses or reocclusions after endovascular treatment of
the above-knee femoro-popliteal artery.23,24 No rando-
mised clinical trial has so far shown any clinical benefit
from folate supplementation. In line with these results, we
found no association between hyperhomocysteinaemia and
cardiovascular events.
FII G20210A and FV Leiden mutations, FVIII levels and
the presence of LAC phenomenon are well-known risk
factors for deep vein thrombosis, but their role in athero-
thrombosis is a matter of debate. Elevated FVIII levels seem
to be associated with higher risk of thrombosis.25 In the
Atherosclerosis Risk in Communities (ARIC) study, individ-
uals with PAD reported higher plasma levels of FVIII,26 but
no study has assessed the association between FVIII plasma
levels and cardiovascular events. In the present study, the
FVIII plasma levels, in the absence of other thrombophilic
alterations, were not associated with outcome.
As previously reported, the prevalence of LAC is higher
in PAD patients than in control subjects.7 The presence of
LAC is associated with arterial thrombosis in patients with
antiphospolipid syndrome27 and LAC and/or anticardiolipin
antibodies (ACAs) are also associated with arterial throm-
bosis in patients with atherosclerotic disease.28 Two longi-
tudinal studies showed an increased risk of mortality in PADpatients when ACA was present.29,30 The presence of anti-
phospholipid antibodies in patients undergoing lower
extremity bypass operations was an independent risk factor
for the progression of PAD.31 In our series, the presence of
LAC seemed to have an impact on PAD prognosis when other
thrombophilic alterations are present.
We recently reported an association between FII
G20210A mutation and CLI.10 The FII 20210A allele has
already been associated with atherosclerosis progression in
carotid and femoral arteries.32 In the present study, most of
the patients with the FII G20210A mutation reached the
‘end’ point but the correlation between such mutation and
the outcome failed, probably due to the small number of
patients. We did not find any association between the FV
Leiden mutation and outcome. However, given the low
number of patients with FV Leiden enrolled in the present
study, we cannot exclude with any certainty an association
between FV Leiden mutations and outcome.
In cardiovascular disease, early detection of rupture-
prone or so-called vulnerable plaques may be essential to
identify the patients at the highest risk of MACE. Vulnerable
plaques tend to occur at multiple sites, and some have
advocated the concept of the vulnerable patient, defined
by high atherosclerotic burden, high-risk/vulnerable pla-
ques or thrombogenic blood.33 It has been reported that
advanced atherosclerotic lesions containing thrombi or the
remnants of thrombi are frequent from the fourth decade
of life onward.34 The components of lesions associated with
thrombus formation cause or facilitate fissures in athero-
sclerotic plaques, and thrombotic deposits on lesions may
also form without an apparent surface defect, haematoma
or haemorrhage.34 Morbidity and mortality from athero-
sclerosis is largely due to such types of lesions. The pres-
ence in a single patient of several thrombophilic alterations
can lead to a ‘prothrombotic’ state. Variations in the
activity of coagulation proteins may alter the effectiveness
of thrombus formation, leading to disease progression and/
or acute vascular events when plaques in the arterial bed
are, already, present.
Several limitations of the present study have to be
acknowledged, such as the limited sample size and the
single-centre cohort. An interaction analysis with the
various classes of anti-hypertensive agents was not per-
formed. Routinely, each patient received combined
platelet aggregation inhibitors for 1 month after PTA, then
a single platelet aggregation inhibitor throughout follow-
up. The patients who did not tolerate aspirin received only
a thienopyridine even in the first month after PTA. This
could have influenced ‘end’ point reaching in the first
months of follow-up. The prevalence of thrombophilia was
different among patients with claudication and with CLI.
This factor could have caused the differences observed in
the outcome, though the association of thrombophilic
alterations with MACE remained after adjustment for
established prognostic markers, such as diabetes or CLI. No
single alteration was associated with the outcome, but
given the limited number of patients enrolled in the
present study, we cannot exclude with certainty any asso-
ciation between single alteration and MACE. Because the
presence of multiple thrombophilic alterations did not
change the care given to patients, thrombophilia screening
in such patients may provide potentially prognostic
822 M. Sartori et al.information. Other studies are needed to demonstrate if
thrombophilic alterations may guide decisions regarding
clinical work-up or therapy intensity.
In conclusion, the presence of two or more thrombo-
philic risk factors may increase the risk of arterial throm-
botic events in patients undergoing PTA for PAD. The
question whether the presence of multiple thrombophilic
alterations requires a different therapeutic approach can
only be evaluated by interventional studies.Acknowledgements
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